Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051).

APR-1051 - Aprea

https://www.asco.org/abstracts-presentations/263989

Shiraj Sen; David Sommerhalder; Anthony Tolcher; Crystal Miller; David Stenehjem; Michael Carleton; Philippe Pultar; Timothy Yap

Apr 21, 2026